Last reviewed · How we verify
Tirofiban+Oral Dual Antiplatelet Therapy
Tirofiban+Oral Dual Antiplatelet Therapy is a Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy Small molecule drug developed by Second Affiliated Hospital of Soochow University. It is currently FDA-approved for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI). Also known as: Tirofiban with Sequential Dual Antiplatelet Therapy.
Tirofiban is a glycoprotein IIb/IIIa inhibitor combined with oral dual antiplatelet therapy to prevent platelet aggregation and thrombotic events through multiple antiplatelet pathways.
Tirofiban is a glycoprotein IIb/IIIa inhibitor combined with oral dual antiplatelet therapy to prevent platelet aggregation and thrombotic events through multiple antiplatelet pathways. Used for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI).
At a glance
| Generic name | Tirofiban+Oral Dual Antiplatelet Therapy |
|---|---|
| Also known as | Tirofiban with Sequential Dual Antiplatelet Therapy |
| Sponsor | Second Affiliated Hospital of Soochow University |
| Drug class | Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Tirofiban blocks the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and platelet cross-linking. When combined with oral dual antiplatelet therapy (typically aspirin and a P2Y12 inhibitor like clopidogrel), this creates a synergistic antiplatelet effect that reduces thrombotic complications in acute coronary syndromes and percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
- Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI)
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
Key clinical trials
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (PHASE4)
- Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke (PHASE4)
- Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tirofiban+Oral Dual Antiplatelet Therapy CI brief — competitive landscape report
- Tirofiban+Oral Dual Antiplatelet Therapy updates RSS · CI watch RSS
- Second Affiliated Hospital of Soochow University portfolio CI
Frequently asked questions about Tirofiban+Oral Dual Antiplatelet Therapy
What is Tirofiban+Oral Dual Antiplatelet Therapy?
How does Tirofiban+Oral Dual Antiplatelet Therapy work?
What is Tirofiban+Oral Dual Antiplatelet Therapy used for?
Who makes Tirofiban+Oral Dual Antiplatelet Therapy?
Is Tirofiban+Oral Dual Antiplatelet Therapy also known as anything else?
What drug class is Tirofiban+Oral Dual Antiplatelet Therapy in?
What development phase is Tirofiban+Oral Dual Antiplatelet Therapy in?
What are the side effects of Tirofiban+Oral Dual Antiplatelet Therapy?
What does Tirofiban+Oral Dual Antiplatelet Therapy target?
Related
- Drug class: All Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy drugs
- Target: All drugs targeting Glycoprotein IIb/IIIa receptor
- Manufacturer: Second Affiliated Hospital of Soochow University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
- Indication: Drugs for Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI)
- Also known as: Tirofiban with Sequential Dual Antiplatelet Therapy
- Compare: Tirofiban+Oral Dual Antiplatelet Therapy vs similar drugs
- Pricing: Tirofiban+Oral Dual Antiplatelet Therapy cost, discount & access